Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA.

In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.

Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conversation also covered a long-term analysis of guselkumab assessing the durability of clinical improvements in joint and skin symptoms in PsA patients over a 2-year period.

ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease Forum

Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.

In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmune diseases, and the potential risks and reservations associated with this therapeutic approach.

ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease Forum

ACR 2024: Preview Podcast by The Immune-Mediated Inflammatory Disease Forum